NovaBay Gross Profit from 2010 to 2024

NBY Stock

USD 0.68 0.04 5.56%

NovaBay Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit NovaBay Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2005-06-30

Previous Quarter

1.6 M

Current Value

1.6 M

Quarterly Volatility

1.3 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of NovaBay Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of NovaBay Pharmaceuticals minus its cost of goods sold. It is profit before NovaBay Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. NovaBay Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 5.64 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

NovaBay Gross Profit Regression Statistics

	Arithmetic Mean	6,841,810
	Geometric Mean	5,373,610
	Coefficient Of Variation	57.82
	Mean Deviation	3,051,556
	Median	6,939,000
	Standard Deviation	3,955,828
	Sample Variance	15.6T
	Range	14.9M
	R-Value	0.25
	Mean Square Error	15.8T
	R-Squared	0.06
	Significance	0.37
	Slope	221,497
	Total Sum of Squares	219.1T

NovaBay Gross Profit History

	2024	8.1 M
	2023	7.9 M
	2022	7.8 M
	2021	5.6 M
	2020	6 M
	2019	4.9 M
	2018	11 M

Other Fundumenentals of NovaBay Pharmaceuticals

Gross Profit Margin

NovaBay Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Total Liab	Net Debt	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	0.45	-0.61	-0.25	-0.16	0.87	0.59	0.3	-0.11	0.0	-0.28	0.17	0.24	-0.17	-0.4	0.09	0.45	0.47	0.25
Total Stockholder Equity	0.83		-0.11	-0.76	-0.04	-0.4	0.88	0.62	0.33	0.06	-0.18	-0.12	0.58	0.1	-0.34	-0.42	0.19	0.5	0.51	0.23
Total Liab	0.45	-0.11		0.06	-0.34	0.37	0.16	0.1	-0.06	-0.29	0.24	-0.29	-0.6	0.25	0.24	-0.02	-0.14	0.04	0.06	0.04
Net Debt	-0.61	-0.76	0.06		-0.39	0.22	-0.86	-0.49	0.19	0.16	0.17	0.21	-0.69	0.3	0.22	0.15	-0.55	-0.29	-0.4	0.35
Retained Earnings	-0.25	-0.04	-0.34	-0.39		-0.06	0.06	-0.08	-0.42	0.05	-0.13	0.05	0.51	-0.94	-0.08	0.31	0.44	-0.42	-0.27	-0.65
Accounts Payable	-0.16	-0.4	0.37	0.22	-0.06		-0.29	0.14	0.09	-0.65	0.23	-0.48	-0.69	0.0	0.05	-0.16	0.12	-0.17	-0.13	0.11
Total Current Assets	0.87	0.88	0.16	-0.86	0.06	-0.29		0.51	0.15	-0.1	-0.02	-0.28	0.51	-0.04	-0.17	-0.17	0.27	0.28	0.32	-0.04
Common Stock	0.59	0.62	0.1	-0.49	-0.08	0.14	0.51		0.19	-0.28	0.05	-0.28	0.06	0.16	-0.61	-0.39	0.12	0.53	0.54	0.37
Property Plant Equipment	0.3	0.33	-0.06	0.19	-0.42	0.09	0.15	0.19		-0.08	0.26	-0.36	-0.19	0.35	-0.08	-0.42	-0.14	-0.02	-0.1	0.79
Current Deferred Revenue	-0.11	0.06	-0.29	0.16	0.05	-0.65	-0.1	-0.28	-0.08		-0.69	0.88	0.28	0.01	0.13	0.39	-0.56	-0.06	-0.06	0.05
Short Term Debt	0.0	-0.18	0.24	0.17	-0.13	0.23	-0.02	0.05	0.26	-0.69		-0.74	-0.28	0.01	-0.17	-0.04	0.19	-0.27	-0.35	0.08
Net Receivables	-0.28	-0.12	-0.29	0.21	0.05	-0.48	-0.28	-0.28	-0.36	0.88	-0.74		0.15	0.06	0.08	0.38	-0.53	0.06	0.05	-0.06
Net Tangible Assets	0.17	0.58	-0.6	-0.69	0.51	-0.69	0.51	0.06	-0.19	0.28	-0.28	0.15		-0.41	-0.13	0.01	0.4	0.14	0.2	-0.39
Capital Surpluse	0.24	0.1	0.25	0.3	-0.94	0.0	-0.04	0.16	0.35	0.01	0.01	0.06	-0.41		0.02	-0.35	-0.43	0.52	0.39	0.67
Deferred Long Term Liab	-0.17	-0.34	0.24	0.22	-0.08	0.05	-0.17	-0.61	-0.08	0.13	-0.17	0.08	-0.13	0.02		0.18	0.12	-0.14	-0.13	-0.07
Short Long Term Debt	-0.4	-0.42	-0.02	0.15	0.31	-0.16	-0.17	-0.39	-0.42	0.39	-0.04	0.38	0.01	-0.35	0.18		-0.39	-0.66	-0.67	-0.43
Cash And Equivalents	0.09	0.19	-0.14	-0.55	0.44	0.12	0.27	0.12	-0.14	-0.56	0.19	-0.53	0.4	-0.43	0.12	-0.39		0.11	0.22	-0.34
Net Invested Capital	0.45	0.5	0.04	-0.29	-0.42	-0.17	0.28	0.53	-0.02	-0.06	-0.27	0.06	0.14	0.52	-0.14	-0.66	0.11		0.98	0.3
Net Working Capital	0.47	0.51	0.06	-0.4	-0.27	-0.13	0.32	0.54	-0.1	-0.06	-0.35	0.05	0.2	0.39	-0.13	-0.67	0.22	0.98		0.19
Capital Stock	0.25	0.23	0.04	0.35	-0.65	0.11	-0.04	0.37	0.79	0.05	0.08	-0.06	-0.39	0.67	-0.07	-0.43	-0.34	0.3	0.19

Click cells to compare fundamentals

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	7.9 M	8.1 M
Gross Profit Margin	0.54	0.80

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC